Exploring the binding affinity of rutin, catechin, and epicatechin to ALK and caspase-3: implications for colorectal cancer treatment

  • I Nyoman Mahesa Praba Adhyaksa Department of Pharmacy, Faculty of Mathematics and Natural Science, Udayana University, Bali, Indonesia
  • Ni Luh Putu Cintya Pramesti Department of Pharmacy, Faculty of Mathematics and Natural Science, Udayana University, Bali, Indonesia
  • Ni Made Pitri Susanti Department of Pharmacy, Faculty of Mathematics and Natural Science, Udayana University, Bali, Indonesia https://orcid.org/0000-0003-4010-1378
  • Ni Putu Linda Laksmiani Department of Pharmacy, Faculty of Mathematics and Natural Science, Udayana University, Bali, Indonesia https://orcid.org/0000-0002-5492-7923
Keywords: anaplastic lymphoma kinase, caspase-3 activation, colorectal cancer, molecular docking, phytochemicals in cancer therapy

Abstract

This study explores the interaction of rutin, catechins, and epicatechins with anaplastic lymphoma kinase (ALK) and caspase-3, focusing on their potential role in modulating the apoptotic mechanisms in colorectal cancer cells. The experimental approach included the preparation of ALK (PDB ID: 5USQ) and caspase-3 (PDB ID: 2XZT), validation of the docking process, optimization of the test compounds, and docking analyses. The molecular docking methodology was validated with an RMSD value of ≤ 3 Å. The docking outcomes revealed that rutin, catechins, and epicatechin exhibited lower binding affinity to ALK, with binding energies of -8.58 kcal/mol, -8.41 kcal/mol, and -7.82 kcal/mol, respectively, compared to ALK's native ligand (-10.27 kcal/mol). Conversely, these compounds demonstrated higher affinity to caspase-3 than its native ligand (-2.54 kcal/mol), with binding energies of -6.03 kcal/mol for rutin, -5.28 kcal/mol for catechins, and -4.95 kcal/mol for epicatechin. These findings suggest that rutin, catechins, and epicatechins hold promise as colorectal anticancer agents by potentially modulating the activity of ALK and caspase-3 through inhibition and activation mechanisms, respectively.

References

Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol. 2021;14: 101174. https://doi.org/10.1016/j.tranon.2021.101174

Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol. 2019;16: 713-732. https://doi.org/10.1038/s41575-019-0189-8

Bavi P, Jehan Z, Bu R, Prabhakaran S, Al-Sanea N, Al-Dayel F, et al. ALK gene amplification is associated with poor prognosis in colorectal carcinoma. Br J Cancer. 2013;109: 2735-2743. https://doi.org/10.1038/bjc.2013.641

Lee J, Kim HC, Hong JY, Wang K, Kim SY, Jang J, et al. Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening. Oncotarget. 2015;6: 24320-24332. https://doi.org/10.18632/oncotarget.4462

Hosono Y, Masuishi T, Mitani S, Yamaguchi R, Kato S, Yoshino T, et al. Evaluation of ALK fusion newly identified in colon cancer by a comprehensive genomic analysis. JCO Precis Oncol. 2019;3: 1-5. https://doi.org/10.1200/PO.19.00268

Eldeeb MA, Fahlman RP, Esmaili M, Ragheb MA. Regulating Apoptosis by Degradation: The N-End Rule-Mediated Regulation of Apoptotic Proteolytic Fragments in Mammalian Cells. Int J Mol Sci. 2018;19. https://doi.org/10.3390/ijms19113414

Alkhalf MI, Alansari WS, Ibrahim EA, ELhalwagy MEA. Anti-oxidant, anti-inflammatory and anti-cancer activities of avocado (Persea americana) fruit and seed extract. Journal of King Saud University - Science. 2018; https://doi.org/10.1016/j.jksus.2018.10.010

Meng X-Y, Zhang H-X, Mezei M, Cui M. Molecular docking: a powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des. 2011;7: 146-157. https://doi.org/10.2174/157340911795677602

Jain AN, Nicholls A. Recommendations for evaluation of computational methods. J Comput Aided Mol Des. 2008;22: 133-139. https://doi.org/10.1007/s10822-008-9196-5

Schroeder T, Barandun J, Flütsch A, Briand C, Mittl PRE, Grütter MG. Specific inhibition of caspase-3 by a competitive DARPin: molecular mimicry between native and designed inhibitors. Structure. 2013;21: 277-289. https://doi.org/10.1016/j.str.2012.12.011

Published
2023-12-31
How to Cite
Adhyaksa, I. N. M. P., Pramesti, N. L. P. C., Susanti, N. M. P., & Laksmiani, N. P. L. (2023). Exploring the binding affinity of rutin, catechin, and epicatechin to ALK and caspase-3: implications for colorectal cancer treatment. Pharmacy Reports, 2(2), 56. https://doi.org/10.51511/pr.56